Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 1/20 | 0.59 |
| ▸ | MAOB | P27338 | 14/20 | 0.58 |
| ▸ | MAOA | P21397 | 8/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA3 | P07451 | 1/20 | 0.56 |
| ▸ | CA4 | P22748 | 1/20 | 0.56 |
| ▸ | CA6 | P23280 | 1/20 | 0.56 |
| ▸ | CA7 | P43166 | 1/20 | 0.56 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1067965 | 0.86 | MAOA (0.64) | SLC16A3MAOBMAOAMEN1NPC1 | |
| SCHEMBL744596 | 0.84 | MAOB (0.76) | SLC16A3MAOBMAOAMEN1NPC1 | |
| SCHEMBL1391034 | 0.84 | SLC16A3 (0.65) | SLC16A3MAOBMAOAMEN1NPC1 | |
| SCHEMBL5866737 | 0.83 | SLC16A3 (0.72) | SLC16A3MAOBMAOAMEN1NPC1 | |
| SCHEMBL17347289 | 0.79 | SLC16A3 (0.62) | SLC16A3MAOBMAOAMEN1NPC1 | |
| SCHEMBL2082378 | 0.78 | FLT3 (0.61) | MEN1NPC1CA12CA1CA2 | |
| SCHEMBL29926214 | 0.78 | MAPT (0.60) | MEN1NPC1KMT2A | |
| SCHEMBL2081885 | 0.77 | HSD11B1 (0.59) | SLC16A3CA12CA1CA2CA9 | |
| SCHEMBL6984136 | 0.76 | POLB (0.51) | MAOBMEN1NPC1KMT2AKDM4E | |
| SCHEMBL93418 | 0.75 | MAOB (0.80) | SLC16A3MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1984360-B1 | Compounds and methods for modulating FX-receptors | LILLY CO ELI (US) | 2014-01-15 | — | — | EP | disclosed |
| US-7863302-B2 | Compounds and methods for modulating FX-receptors | ELI LILLY AND COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-20080306125-A1 | Compounds and Methods for Modulating Fx-Receptors | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2008-12-11 | — | — | US | disclosed |
| EP-1984360-A2 | COMPOUNDS AND METHODS FOR MODULATING FX-RECEPTORS | Eli Lilly & Company (US) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007092751-A2 | COMPOUNDS AND METHODS FOR MODULATING FX-RECEPTORS | ELI LILLY AND COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306125-A1 | Compounds and Methods for Modulating Fx-Receptors | F2R, TBXA2R, PTAFR | SLC16A3 4002/4885MAOB 583/4885MAOA 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.